A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer.

Trial Profile

A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Rilimogene galvacirepvec (Primary) ; Samarium-153-SM-lexidronam (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
    • 16 Feb 2013 This trial was closed early due to poor accrual.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top